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ABSTRACT 
Background 
Cardiovascular disease (CVD) is the leading cause of death worldwide, particularly amongst 
ageing males. Prevention and/or early identification and effective intervention are essential in 
the fight against CVD. Erectile dysfunction (ED) is a prevalent and multi-factorial condition that 
is now accepted to be an early marker of subclinical CVD: the common denominator is 
endothelial dysfunction. Both the enzymatic capability for bioactivation of vitamin D and the 
vitamin D receptor (VDR) are expressed in endothelial cells and vitamin D may play a role in 
endothelial function. Vitamin D deficiency (serum 25-hydroxyvitamin D (25(OH)D) 
concentrations ˂50 nmol/L) is a worldwide pandemic and serum 25(OH)D levels ˂75 nmol/L 
may result in metabolic and vascular deterioration leading to endothelial dysfunction, ED and 
CVD. Assessment of erectile function can be used to identify otherwise asymptomatic men at 
high risk of developing clinical CVD, at a time when effective intervention may prevent, delay 
or reverse its progression. Vitamin D status may be associated with ED and CVD risk and could 
help improve erectile function and vascular health.  
Objectives 
The aim of this research was to investigate the postulated link between vitamin D status, ED, 
and CVD risk factors. The objectives were (1) to assess the prevalence of ED (using the 5-item 
International Index of Erectile Function (IIEF-5)) and its associated sociodemographic, lifestyle, 
and medical correlates in New Zealand (NZ) men aged 40-70 years; (2) to investigate the 
relationship between vitamin D status (serum 25(OH)D concentration), ED and other CVD risk 
factors in men aged 40-70 years living in the Manawatu region of NZ; and (3) to examine the 
impact of common VDR gene (VDR) polymorphisms on this relationship.  
Method 
Two thousand men aged 40-70 years were randomly selected from the NZ Electoral Roll and 
sent an anonymous postal survey designed to assess the prevalence of ED and its 
sociodemographic, lifestyle, and medical risk factors. Six hundred men aged 40-70 years living 
in the Manawatu region were randomly selected from the NZ Electoral Roll and invited to 
participate in an observational study designed to provide a comprehensive health profile of 
self-reported healthy men and investigate the relationship between vitamin D status, ED, and a 
range of CVD risk factors. Eligible participants (n=100) completed a comprehensive health 
assessment including a medical history, anthropometric and cardiovascular assessment, fasting 
blood sample, computer-based questionnaire, a submaximal fitness test and a handgrip 
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strength test. Blood samples were assessed for four common VDR polymorphisms (rs11568820 
(Cdx2), rs10735810 (FokI), rs1544410 (BsmI) and rs731236 (TaqI)) using polymerase chain 
reaction-high resolution amplicon melt (PCR-HRM) analysis.  
Results 
The survey showed 38.4% of respondents presented with ED (IIEF-5 ≤21). Older age, non-
European ethnicity and current smoking were significant independent predictors of an 
increased risk of ED, while a high household income and regular vigorous physical activity (PA) 
were deemed protective. The observational study showed 30 men presented with ED and a 
further 37 men had <75 nmol/L 25(OH)D. There was a weak positive correlation between IIEF-
5 scores and 25(OH)D levels (rs=0.238, p=0.017). Men with <75 nmol/L had lower IIEF-5 scores 
compared to men with ≥75 nmol/L 25(OH)D (22(7) vs. 24(3), p=0.001). Men with ED had lower 
25(OH)D levels compared to men without ED (74.5(34) vs. 84.5(24), p=0.062). Every 1 nmol/L 
of 25(OH)D predicted a 2% decrease in the age-adjusted risk of ED (age-adjusted OR=0.98 
[0.96-1.00], p=0.046). The PCR-HRM analysis showed that the Cdx2, FokI and BsmI 
polymorphisms were all significantly associated with an adverse cardiovascular risk profile. The 
Cdx2 G allele was associated with lower IIEF-5 scores compared to the A allele (23(4) vs. 24(2), 
p=0.008) and the GA and GG genotypes were predictors of an increased age-adjusted risk of 
ED (age-adjusted OR=18.78 [1.98-178.60], p=0.011 and 8.53 [1.00-72.73], p=0.050 
respectively). However, Cdx2 was not found to modify the age-adjusted association between 
25(OH)D levels and ED (multi-adjusted OR=0.97 [0.95-1.00], p=0.032).  
Conclusions 
These results suggest that over a third of NZ men aged 40-70 years suffer from ED and it is 
associated with sociodemographic, lifestyle and medical factors simliar to CVD. Low serum 
25(OH)D is associated with the presence and severity of ED in a self-reported healthy 
population. Common VDR polymorphisms are also associated with ED; however, they do not 
modify the association between serum 25(OH)D and ED. A randomised placebo-controlled 
human intervention trial is warranted to investigate whether improving vitamin D status in 
men with vitamin D deficiency and ED ameliorates symptoms and reduces the risk of CVD.  
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